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Abstract. Isoxyl is a potent antituberculosis drug effective in treating various multidrug-resistant strains
in the absence of known side effects. Isoxyl has been used exclusively, but infrequently, via the oral route
and has exhibited very poor and highly variable bioavailability due to its sparing solubility in water.
These properties resulted in failure of some clinical trials and, consequently, isoxyl’s use has been limited.
Delivery of isoxyl to the lungs, a major site of Mycobacterium tuberculosis infection, is an attractive
alternative route of administration that may rescue this abandoned drug for a disease that urgently
requires new therapies. Particles for pulmonary delivery were prepared by antisolvent precipitation.
Nanofibers with a width of 200 nm were obtained by injecting isoxyl solution in ethanol to water at a
volume ratio of solvent to antisolvent of 1:5. Based on this preliminary result, a well-controlled method,
involving nozzle mixing, was employed to prepare isoxyl particles. All the particles were 200 to 400 nm in
width but had different lengths depending on properties of the solvents. However, generating these
nanoparticles by simultaneous spray drying produced isoxyl microparticles (Feret’s diameter, 1.19–
1.77 μm) with no discernible nanoparticle substructure. The bulking agent, mannitol, helped to prevent
these nanoparticles from agglomeration during process and resulted in nanoparticle aggregates in
micron-sized superstructures. Future studies will focus on understanding difference of these isoxyl
microparticles and nanoparticles/nanoparticle aggregates in terms of in vivo disposition and efficacy.
KEY WORDS: antisolvent precipitation; multidrug resistant; pulmonary delivery; spray drying;
tuberculosis.
INTRODUCTION
Tuberculosis is the leading cause of death by a single
infectious microorganism. One third of the world’s population
has been infected by tuberculosis, with 9.27 million new cases
and 1.8 million deaths in 2007 according to World Health
Organization report 2009 (1). The availability of the vaccine
Bacillus Calmette–Guerin and curative chemotherapies were
responsible for the general decrease in tuberculosis mortality
in the past century. Nevertheless, the frequency of occurrence
of new cases began to increase in the mid-1980s. Two main
factors contribute to the resurgence of tuberculosis, the
occurrence of immunosuppressive diseases, human immuno-
deficiency virus infections, and the emergence of multidrug-
resistant (MDR) strains, which are resistant to isoniazid and
rifampicin, two first-line antituberculosis drugs (2–5).
Pulmonary tuberculosis is a major manifestation of
tuberculosis implicated in morbidity and systemic dissemina-
tion. However, when antitubercular drugs are administered
orally, drug concentrations in plasma and the lungs are well
below the suggested therapeutic range in some patients (6–8).
Additionally, the fraction of an oral dose of drug delivered to
the lungs that can access granulomas, tubercles, or lesions
which have very poor blood supply may be small (9). This
suboptimal drug concentration contributes to prolonged
duration of treatment, relapse, and development of MDR
strains. In comparison, inhalation of drugs can avoid this
malabsorption in the following ways: (1) Drugs can achieve
higher lung tissue to plasma concentration ratio (10); (2)
hydrophobic drugs have higher solubility and more rapid
dissolution rates in the surface lining fluid containing large
quantities of lung surfactants (11); (3) the lungs are thought to
have fewer metabolizing enzymes and efflux transporters in
contrast to the gastrointestinal tract where orally adminis-
tered drugs undergo first-pass effects of the gut and liver (12);
and (4) more importantly, drug particles delivered to the
lungs have been shown to target to macrophages/monocytes,
the host cells for Mycobacterium tuberculosis (MTB) (13).
Isoxyl (ISO, thiocarlide, 4,4′-diisoamythio-carbanilide) is
a second-line drug used clinically to treat tuberculosis in the
1960s. It is a potentially efficient antituberculosis drug for
treatment of the MDR strains in monotherapy or in a
combined regimen. In vitro studies showed that isoxyl have
strong antimycobacterial activity with minimum inhibitory
concentration (MIC) of 2.5 µg/ml for MTB H37Rv and MIC
of 1–10 µg/ml for various clinical isolates of strains resistant to
rifampicin and isoniazid (14). However, the effectiveness of
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isoxyl has been questioned due to failure in some clinical
trials (15,16). The most plausible explanation for these
failures is that isoxyl is almost completely insoluble in water
(solubility calculated by advanced chemistry development
(ACD/labs) software V8.14 for Solaris: 1.3×10−6 mol/L at
25°C) and, consequently, exhibits poor dissolution and
bioavailability when it is delivered exclusively by the oral
route. Efforts to improve the oral absorption of isoxyl,
including use of micropowders or suspension in olive oil,
etc., resulted in no improvement of isoxyl absorption, and the
majority of the administered dose was still eliminated intact
via the feces (17,18). Pulmonary delivery of isoxyl may be an
effective approach to rescue this abandoned drug.
Particle size distribution impacts on drug deposition
and disposition. Microparticles with aerodynamic diameter
between 1 and 5 μm are delivered from dry powder
inhalers to the lungs (19,20) where they are efficiently
phagocytized by alveolar macrophages (13,21,22). Target-
ing to alveolar macrophages is known to enhance efficacy
due to specific drug action at the main site of infection
(23) and through macrophage activation (24). In contrast
to microparticles, nanosuspension can be given by nebu-
lization. It was reported that particles smaller than 500 nm
in diameter were phagocytized by alveolar macrophages to
a smaller extent than 1–5 μm microparticles (13,22,25).
Dendritic cells may take up these nanoparticles (9), but
the kinetics of this phenomenon will be influenced by
rapid dissolution of the particles in alveolar lining fluid.
Consequently, a portion of nanoparticles may escape from
monocyte uptake, which leads to an increase in systemic
drug exposure. A balance between phagocytosis and
dissolution would be beneficial for tuberculosis therapy.
Tuberculosis is a systemic infection, which might benefit
from higher concentrations of isoxyl in the lungs while
requiring maintenance of therapeutically effective plasma
concentrations.
This paper describes optimization of antisolvent pre-
cipitation conditions with or without simultaneous spray
drying to produce isoxyl particles with diverse particle size
distributions and morphology suitable for lung delivery.
Antisolvent precipitation is a simple method, by which the
crystallinity of drugs can be controlled and high drug
loadings can be achieved. Precipitation of particles can be
induced by introducing a large quantity of antisolvent to
drug solution, which results in effectively instantaneous
lowering of solvent capacity to solubilize drug (26). The
mechanism of precipitation includes three processes: nucle-
ation, coagulation, and condensation. Addition of antisol-
vent to the drug solution creates high degree of local
supersaturation, which leads to the formation of many
small nuclei (27,28). These nuclei then undergo growth by
condensation and coagulation until reaching an equilibrium
(26). Therefore, the solid-state properties including particle
size distribution and morphology of the resulting precip-
itants can be influenced by the factors that have impact on
the rates of these three processes (26,29). Spray drying
generated dry powders from particle suspension following
antisolvent precipitation. In the spray-drying process,
particle size and shape can also be changed by varying




Isoxyl was purchased from Cayman Chemical Co. (Ann
Arbor, MI, USA). Acetone and isopropanol were obtained
from Fisher Scientific. D-mannitol and ethanol were from
Sigma. Tetrahydrofuran (THF) was from EM Science (Darm-
stadt, Germany). Lactose (Respitose® ML001) was provided
by DMV internal. Flexi-Dry™ freeze-dryer was from Kinetics
Group (Santa Clara, CA, USA). The three-fluid nozzle was
purchased from Buchi Labortechnik AG (Flawil, Switzer-
land) and fit in a BUCHI B-191 mini-spray drier made by the
same manufacturer. Isopore™ polycarbonate membrane
filter (pore size, 0.1 μm; Millipore, Billerica, MA, USA) or a
Cyclopore polycarbonate membrane filter (pore size, 0.1 μm,
Whatman, Florham Park, NJ, USA) was used to collect
particles in suspensions. Water was deionized by Barnstead
Nanopure Infinity Ultrapure Water System (Dubuque, IA,
USA). Either scanning electron microscopy (SEM; JSM
6,300 V SEM, JEOL USA, Peabody, NY, USA) or SEM
(Hitachi S-4700 cold cathode field emission SEM) was used to
visualize the particles. Laser diffraction (LD, Series 2600C
Malvern Instruments, Malvern, UK) and dynamic light
scattering (Nicomp particle sizing systems, AutodilutePAT
Model 370, Santa Barbara, CA, USA) were utilized to
measure microparticle and nanoparticle size distributions,
respectively. Thermal properties of isoxyl were measured by
differential scanning calorimetry (DSC, Perkin Elmer DSC 6,
Waltham, MA, USA).
Particle Manufacture
1. Particles precipitated from the injection method: The
preliminary screening of precipitation conditions was
performed by injecting isoxyl (1 mg/ml) solution in
ethanol into the aqueous phase manually at a speed of
approximate 15 ml min−1 during magnetic stirring using
a 27-gauge sterile needle with a 10-ml disposable
syringe. The tip of the needle was located just above
the stir bar to achieve maximum mixing. Three volume
ratios of solvent to antisolvent (VRSAs) were assessed:
1:1, 1:2, and 1:5. All the above procedures were
conducted at room temperature. The resulting isoxyl
particle suspensions were centrifuged (Beckman Model
CS-15R) at 8,000–9,000 rpm for 10 min and then the
supernatants were discarded. The pellets were
transferred to the freeze-dryer (temperature, <−50°C
and pressure, <0.05 mbar) and dried for 24 to 48 h.
2. Particles precipitated from the nozzle-mixing
method: Solvent and antisolvent at a VRSA equal
to 1:5 were mixed by a three-fluid nozzle. Isoxyl
concentrations in ethanol, isopropanol, acetone, and
THF were 11, 7, 100, and 100 mg/ml, respectively.
This was determined by solubility of isoxyl in these
solvents. All the other antisolvent precipitation
conditions were kept constant: organic feed rate
0.2 ml/min, water feed rate 1 ml/min, nitrogen flow
rate 400 L/min, and atomization pressure 3 bar.
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Atomized fine droplets from the 0.7-mm diameter
nozzle were sprayed directly into 50 ml quenching
water. Dynamic light scattering was used to measure
particle size distribution in the suspensions. The
particles in suspension were collected by filtering
through a membrane filter. The filters were com-
pletely dried in a vacuum desiccator and used
immediately for SEM.
3. Spray-dried particles from the nozzle-mixing method:
The effects of processing parameters on particle
characteristics were evaluated utilizing a 27-4 factorial
design. Eight manufacturing runs were conducted and
randomized by Design Expert® (Table I). For all the
studies, the aspirator rate of the spray drier was kept
at 90% of maximum flow (approximately 35 m3 h−1).
Water and isoxyl solution in either isopropanol or
ethanol were delivered to the three-fluid nozzle and
then sprayed into a BUCHI B-191 mini-spray drier.
The particles impacted on the bottom of cyclone
(<8 cm from the bottom edge) and collecting vessel
and were collected and subsequently characterized.
In addition to alcohol, THF as solvent was also
evaluated. Isoxyl was dissolved in THF at a concen-
tration of 100 mg/ml and spray dried using the
following condition: organic feed rate 0.5 ml/min,
water feed rate 1.8 ml/min, atomization pressure
3 bar, nitrogen flow rate 600 L/min, and aspirator
rate 90% of maximum flow.
The use of the bulking agent, mannitol, was assessed.
The isoxyl solution (7.2 mg/ml) of 4 ml and water were
mixed in the three-fluid nozzle under the following
conditions: organic feed rate 0.3 ml/min, water feed
rate 1.7 ml/min, nitrogen flow rate 400 L/min, and
atomization pressure 3 bar. The mixture was directly
sprayed into 200 ml of mannitol solution (0.63 mg/ml).
This resulted in the ratio of isoxyl to mannitol equal to
1:4.4. The dried particles were resuspended in water
to dissolve mannitol. Particle size distributions were
measured by dynamic light scattering. To visualize
these particles, the suspension was filtered by a
membrane filter. The filter was washed with a large
quantity of water at least three times to remove
residual mannitol and then dried in a vacuum
dessicator to be ready for SEM.
Characterization
1. Particle size and morphology: The primary particle
size, shape, and surface morphology of the isoxyl
particles were examined by SEM. The lyophilized
particles and commercial isoxyl powders were
employed as controls and directly applied to conduc-
tive double-sided tapes attached to aluminum stubs.
The spray-dried particles are first suspended in water
and sonicated for 30 s. Small drops of the particle
suspensions were placed on the tape and dried in a
vacuum desiccator. The filters containing nanopar-
ticles were cut to fit and placed on the tapes. All the
samples were sputter-coated using either a Polaron
5200 (Structure Probe Supplies, West Chester, PA,
USA) or a Cressington 108 with a Cressington MTM-
10/10A high resolution film thickness monitor (Cres-
sington Scientific Instruments, Cranberry, PA, USA)
with gold–palladium alloy, and micrographs of the
particles were taken. The primary particle size distri-
butions and circularities were calculated by Image J
program (Image Processing and Analysis in Java,
created by NIH image for Macintosh). Here, the
circularity indicates degree of particle elongation and
a value approaching unity means that the particles are
nearly spherical.
LD was used to measure microparticle size distribu-
tion, by volume. Briefly, the microparticles were
suspended in water and sonicated for 1–2 min. The
suspensions were added dropwise in a stirred sample
cell containing distilled water until an obscuration
level of about 10% to 20% were achieved. Nano-
suspensions from precipitation or particle in mannitol
matrix were redispersed in water, and nanoparticle
size distributions were measured by dynamic light
scattering.
2. Thermal properties of spray-dried microparticles: Ther-
mal profiles of unprocessed isoxyl powder and a batch of
spray-dried isoxyl microparticles (condition 8) were
subjected to DSC, in which nitrogen at a flow rate of
30 ml/min was the purge gas. The samples were sealed in
standard aluminum pans and heated from 21°C to 250°C
at scanning rates of 40°C/min and 5°C/min.














1 Isopropanol 0.3 1.8 2 120 3 600
2 Ethanol 0.3 0.7 5 120 6 600
3 Isopropanol 0.3 0.7 2 100 6 800
4 Ethanol 0.7 1.8 2 100 6 600
5 Ethanol 0.3 1.8 5 100 3 800
6 Ethanol 0.7 0.7 2 120 3 800
7 Isopropanol 0.7 1.8 5 120 6 800
8 Isopropanol 0.7 0.7 5 100 3 600
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3. Fine particle fraction (FPF) and emitted dose: Aero-
solization of the lyophilized isoxyl particles from the
injection method, the spray-dried particles (condi-
tion 8), and control from commercial source were
determined. Lactose carrier was added by mixing
isoxyl microparticles at a concentration of 1% w/w
(Fischer Scientific hematology/chemistry mixer, model
346) for 10 min. Isoxyl powders of approximately 1 mg
with or without lactose carrier were filled into the
gelatin capsule (product size no. 3; Capsugel, Peapack,
NJ, USA) and then placed in an Inhalator® (Boeh-
ringer Ingelheim). A twin-stage liquid impinger was
employed to evaluate deposition of the isoxyl par-
ticles. The impinger (7 and 30 ml of ethanol were
placed in the upper and the lower stages) was
assembled to be airtight and vertical. After turning
on the pump providing airflow of 60 L/min, isoxyl
powder was released from the inhalator. The pump
was turned off 10 s after emission. After disassembling
the apparatus, the capsule shell, the inhaler device, the
mouthpiece, the throat, and the upper and lower
stages were all thoroughly washed with ethanol
separately. When isoxyl was dissolved in ethanol, the
absorption maximum wavelength was 273.5 nm. The
concentration of isoxyl in each sample was determined
by UV spectrometry at a wavelength of 273.5 nm
based on standard curves (R>0.99). Several parame-
ters of the deposition profile of each isoxyl powder
were calculated: the emitted dose is the total drug
mass leaving the device (the sum of the amount of
isoxyl in the mouthpiece, the throat, and the two
stages); the recovered dose (RD) includes emitted
dose and the amount in the capsule shells and the
inhalator device; the fine particle dose (FPD) is the
amount of isoxyl in the lower stage, which contains
particles (≤6.4 μm aerodynamic diameter); the FPF is
the ratio of the FPD to RD; the percent recovery is
the ratio of RD to the expected dose; the dispersibility
is the ratio of FPD to emitted dose; and the percent
emission is the ratio of emitted dose to RD (31).
Fig. 1. Scanning electron photomicrographs of a commercial isoxyl (lot no. 130365–149120) at ×50 magnification, b commercial isoxyl (lot no.
130365–149120) at ×1,400 magnification, c commercial isoxyl (lot no. 165311–167669) at ×100 magnification, and the isoxyl particles from
antisolvent precipitation by injection method: d VRSA=1:1 at ×700 magnification, e VRSA=1:2 at ×700 magnification, and f VRSA=1:5
at ×15,000 magnification
Table II. The Count Median Diameter (CMD) of the Shortest Dimension and the Geometric Standard Deviation (GSD) of the Elongated




(lot no. 165311–167669) VRSA=1:1 VRSA=1:2 VRSA=1:5
Width CMD (μm) 1.47 3.95 3.30 0.88 0.22
GSD 1.88 1.57 1.68 2.03 1.55
Length CMD (μm) 8.2 178 17.0 ND 0.99
GSD 1.90 2.48 1.91 ND 1.66
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RESULTS
Particle Size Distribution and Morphology
1. Particles precipitated from the injection method: As
shown in Fig. 1 and Table II, the commercial isoxyl
powder consisted of either large needle-shaped
agglomerates (lot no. 130365–149120) or extremely
long needle-shaped particles (lot no. 165311–167669)
with heterogeneous distributions. Depending on dif-
ferent lots, these particles may form agglomerates
with diameters up to a few hundred microns. When
isoxyl was precipitated by the injection method from
the mixture of VRSA of 1:1, the particles were needle-
shaped with count median diameter of 3.3 μm in width
and were more loosely aggregated compared to
commercial isoxyl. The antisolvent precipitation when
VRSA was equal to 1:2 generated both flake-shaped
and needle-shaped particles. Changing VRSA to 1:5
yielded elongated particles with shortest dimension of
220 nm (Fig. 1 and Table II).
2. Particles precipitated from the nozzle-mixing
method: Depending on organic solvents, isoxyl par-
ticle size and morphology were different as shown in
Fig. 2 and Table III: ethanol generated nanofibers
(width=385 nm, circularity=0.72); isopropanol and
THF produced oblate spherical particles (width=
275 nm and circularity=0.89 for isopropanol, width
=220 nm and circularity=0.87 for THF); and acetone
yielded both nanofibers (width=200 nm, circularity=
0.4) and oblate spherical nanoparticles (width=






Circularity 0.72 0.89 0.87 0.40 0.98
Width CMW (nm) 385 275 220 200 285
GSD 1.5 1.47 1.76 1.44 1.3
Length CML (nm) 1,280 495 450 1,190 390
GSD 1.72 1.61 1.63 1.66 1.5
PSD particle size distribution, CMW count median width, CML count median length, GSD geometric standard deviation
Fig. 2. Scanning electron micrographs of isoxyl particles precipitated from ethanol a, isopropanol b,
acetone c, and tetrahydrofuran d. The micrographs were taken at ×500 magnification
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285 nm, circularity=0.98). Isopropanol was the first
choice of solvent for further optimization of nano-
particle preparation because they produced most
homogenous nanoparticles with a diameter <500 nm.
3. Spray-dried particles from the nozzle mixing: The
modified spray drier produced approximate spherical
particles with count median diameters (Feret’s diam-
eter (32)) between 1.19 and 1.77 μm in these eight
Fig. 3. Scanning electron photomicrographs of the spray-dried isoxyl particles produced by nozzle mixing of isoxyl solutions and water. a–h The
particles from conditions 1–8, respectively, in Table I, and i is those from using tetrahydrofuran as solvent. The photomicrographs were taken
at ×3,000 magnification
Table IV. Summary of Particle Size Distributions and Circularities Produced in the Eight Conditions
1 2 3 4 5 6 7 8
Yield 19.7 29.3 11 25 18.2 11.4 20 28.6
SEM CMD (μm) 1.25 1.24 1.82 1.57 1.33 1.19 1.67 1.77
GSD 2.01 1.58 1.75 1.34 1.21 1.26 1.47 1.48
Circularity 0.95 0.93 0.91 0.95 0.91 0.95 0.95 0.98
LD Dv,10 (μm) 1.88 1.84 1.98 1.81 1.54 1.86 1.77 1.81
Dv,50 (μm) 2.20 2.16 2.44 2.13 1.81 2.09 2.02 2.14
Dv,90 (μm) 6.43 5.78 7.09 6.05 2.36 2.32 2.28 2.67
Span 2.06 1.82 2.09 1.98 0.45 0.22 0.26 0.4
PSD particle size distribution, CMD count median diameter, GSD geometric standard deviation, Circularity 4π•(area per square perimeter),
Dv,10 particle size at tenth percentile of the cumulative distribution, Dv,50 particle size at 50th percentile of the cumulative distribution, Dv,90
particle size at 90th percentile of the cumulative distribution, Span (Dv,90−Dv,10)/Dv,50
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conditions. The average circularity of the micropar-
ticles in each condition was approximate to unity, and
those from condition 8 were almost perfect spheres
(Fig. 3a–h and Table IV). The particle size distribu-
tions, by LD, were unimodal for conditions 5 to 8,
bimodal for conditions 2 and 4, and multimodal for
conditions 1 and 3. Conditions 5 to 8 resulted in 100%
of the particles having diameters <5 μm; conditions 1
to 4 resulted in 70–80%<5 μm (Fig. 4). The yields of
the spray-drying conditions varied from 11.0% to
29.3% (Table IV). Statistical experimental design
and analysis showed that isoxyl concentration and
nitrogen flow rate were two critical factors influencing
the yield: an increase in isoxyl concentration and
decrease in nitrogen flow rate resulted in greater
yield. However, statistical analysis could not identify
any key factors influencing particle size distribution
and morphology (Fig. 5). THF was evaluated as a
solvent. Unfortunately, this produced much larger
plate-shaped particles with heterodisperse particle size
distribution (Fig. 3i). Condition 8 appeared to achieve
the desired high yield, spherical shape, and narrow
particle size distribution.
The addition of mannitol reduced the particle size.
When the drug ratio to mannitol is 1:4.4, themean count
diameter of the isoxyl particles determined by DLS was
455 nm, and standard deviation was 299 nm (Fig. 6a).
However, SEM micrographs showed that these isoxyl
particles were heterogeneous: some particles were
almost spherical, while others were elongated (Fig. 6b).
Further studies are required to produce nanoparticle
aggregates with uniform shape and size.
Fig. 4. Particle size distributions of the isoxyl particles measured by laser diffraction (LD).
a–h represent particles from spray drying condition 1–8
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Thermal Properties
At a scanning rate of 40°C/min, the DSC thermogram
of unprocessed isoxyl powder showed two peaks at 95.8°C
and 149.7°C (ΔH=98.6 J/g), which corresponded to the
boiling point of residual ethanol and melting point of isoxyl
crystal form I, respectively. Isoxyl microparticles from
antisolvent precipitation and consequent spray drying
exhibited only one peak at 143.5°C (ΔH=76.3 J/g) corre-
sponding to crystal form II (Fig. 7a). This may be
explained by the processing conditions removing residual
ethanol and converting isoxyl from form I to form II. For
the scanning rate of 5°C/min, the DSC thermogram
revealed the same results except that the peaks of crystal
form I, II, and ethanol shifted to 140.5°C, 136.2°C, and
80.2°C (Fig. 7b).
Fig. 5. Half normal plot of effects of processing parameters on count median diameter a, geometric
standard deviation b, circularity c, and yield d of spray-dried isoxyl particles. In the selected range, only
yield was influenced by the processing parameters, N2 flow rate (P=0.0025), and isoxyl concentration (P=
0.0005). e Square plot of effect of these two parameters on yield
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Fine Particle Fraction and Emitted Dose
1. Particles precipitated from the injection method: The
isoxyl particles, which were prepared by injecting
isoxyl solution into water and sequentially lyophiliz-
ing, exhibited good emitted dose performance of
74.90–78.46% and FPF of 8.76–12.57% (Table V).
2. Spray-dried particles from the nozzle mixing: The
aerodynamic particle size of the isoxyl microparticles
produced in condition 8 was determined. The power
had an emitted dose of 94% and a very low FPF of
5.4%. Therefore, cohesive forces of isoxyl micro-
particles were too high to achieve efficient deaggre-
gation during aerosol dispersion. Addition of lactose
carrier increased FPF of the isoxyl particles to 8.4%
(Table VI).
DISCUSSION AND FUTURE STUDIES
The commercial isoxyl consisted of either large fiber
agglomerates or long fibers several hundred micrometers in
length. Although the sizes of these fibers exceed the
respiratory range, they can still be delivered to the lungs,
due to their unique aerodynamic properties, as indicated
by FPF of 6.9%. The main reason is that aerodynamic
diameters of the fibers are predominantly a function of
their cross-section area diameter or diameter of the small-
est dimension. Despite relatively high delivery efficiency,
these fibers are not suitable for inhalation therapy: It has
been well established that toxicity of certain fibers depends
on particle dimension and biopersistence instead of chem-
ical properties. It was reported that occurrence of pleural
sarcoma was high in rats when the fibers were more than
4 µm long (32). One mechanism of fiber carcinogenesis is
due to cell transformation. After these long fibers were
phagocytized, they persist in the perinuclear region of
macrophages and induce chromosomal mutations and,
consequently, cell transformation (33). Also, persistence
of fibers in the lungs can cause cancer and fibrosis.
Macrophages cannot take up fibers much longer than their
cell dimension. Phagocytosis was incomplete when the rat
alveolar macrophages were exposed to fiber of 17 µm in
length (34). The cut-off length of fibers causing frustrated
phagocytosis by human alveolar macrophages was expected
to be longer than 20 µm, because alveolar macrophages in
human (diameter, ∼18 µm) are larger than rats (diameter,
∼13 µm) (35). Incomplete phagocytosis leads to persisting
of these insoluble fibers in the lungs. As shown in
“RESULTS,” commercial isoxyl particles are so long that
they can be potentially persistent in the lungs and cause
toxic effects. In the study, antisolvent precipitation was used
to break down these long isoxyl fibers.
By simply injecting isoxyl solution into aqueous phase,
the drug was precipitated out as needle-shaped particles. It
was found that VRSA was a critical factor controlling
particle size. Keeping other parameters consistent, isoxyl
Fig. 6. Particle size distribution a and scanning electron microscopy b of the spray-dried isoxyl particles
produced by addition of mannitol (isoxyl:mannitol=1:4.4)
Fig. 7. Differential scanning calorimetry thermograms of commercial isoxyl (gray) and isoxyl microparticles
(black) prepared by spray drying using condition 8. The scanning rates were 40°C/min a and 5°C/min b
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particle size decreased from the micron to the nano range
as the VRSAs were changed from 1:1 to 1:5. This is
explained by increase in local supersaturation ratio (S) and
retardance in particle growth kinetics (36). Here, the local
supersaturation is defined by the ratio of local drug
concentration to the equilibrium solubility of drug in the
mixture of solvent–antisolvent. After isoxyl ethanol solu-
tion was injected to water, solubility of the drug decreased
much more in 16% ethanol (VRSA=1:5) than that in 50%
ethanol (VRSA=1:1). This led to higher local supersatura-
tion ratio in 16% ethanol and consequentially smaller
nuclei. However, isoxyl nuclei were in a more dilute
environment in 16% ethanol compared to 50%, which
slowed down crystal growth. As a result, when VRSA was
equal to 1:5, isoxyl particles were the smallest. In addition,
the width of these particles was about 200 nm. This
increased surface area dramatically in comparison to
microsphere of the same volume, which can in turn reduce
the residence time of particles in the lungs through rapid
dissolution in the lung lining fluid. However, it remains to
be seen whether the rapid dissolution is sufficient to
achieve therapeutic isoxyl concentration systematically. If
that is not true, microparticle targeting to the infected cells
may be advantageous with respect to the rapid dissolution
of nanoparticles and subsequent elimination of drug from
the lungs before tissue penetration for therapy can occur.
The nozzle-mixing method was used to achieve uniform
mixing that was hard to obtain by the manual injection
method. The appropriate solvent was screened when adopt-
ing a VRSA of 1:5. Four organic solvents, ethanol, isopropa-
nol, acetone, and THF, were selected due to their low toxicity
in trace quantities. As expected, physicochemical properties
of solvents were key factors controlling particle size and
crystal habit. One explanation for this observation is the
difference between these solvents in degree of miscibility with
water, a function of supersaturation. Better miscibility
resulted in higher supersaturation and smaller particle size.
Also, it has been reported that an increase in supersaturation
tends to form elongated particles (37). This may explain the
greater production of elongated particles from ethanol or
acetone than isopropanol or THF, because isopropanol is
more hydrophobic than ethanol, and acetone is completely
miscible with water but THF is not. However, the effect of
solvent can be complicated by other properties such as
hydrogen bonding, dipole moment, and dielectric constant,
which facilitate crystal growth predominately in one dimen-
sion (29). Isopropanol delivered the best product: oblate
spherical nanoparticles <500 nm in length with the most
homogeneous distribution.
The precipitating particles can be simultaneously spray
dried. The initial aim was to collect the precipitating nano-
particle in the form of aggregates. The preparation of isoxyl
particles in the study consisted of two processes: antisolvent
precipitation and simultaneous spray drying, which were
controlled by seven main factors: type of solvent, organic
feed rate, water feed rate, inlet temperature, drug concen-
tration, nitrogen pressure, and flow rate. Effects of these
factors on particle size were evaluated in a statistically
designed experiment. However, isoxyl nanoparticle aggre-
gates could not be obtained by simply varying these operating
conditions since nano-sized precipitates agglomerate into
microparticles in the process. It appeared that primary sizes
of the particles were determined by amount of isoxyl in the
atomized droplets independent of the precipitate size. There-
fore, the median diameter of the spray-dried isoxyl particles
can be predicted by Eq. 1 (38):






Here dparticle and ddroplet are the spray-dried particle
diameter and the atomized droplet diameter. C is the con-
centration of isoxyl in the mixture of solvent and antisolvent,
and ρparticle is density of the particle. According to the
information from the manufacturer (Buchi Labortechnik AG,
Flawil, Switzerland), median volume diameters of the atom-
ized droplets should be 10.48 μm when nitrogen flow rate is
830 L/h and 30.6 μm when nitrogen flow rate is 440 L/h.
Assuming the median volume diameter of the atomized
droplets is around 20 μm for 600 L/h and density of isoxyl is
close to 1 µg/ml, the median diameter of resulting isoxyl
particles is predicted to be between 0.92 and 2.7 μm, which
is consistent with the experimental results. This also
explains the production of larger microparticles when THF
was used as solvent. Isoxyl has a higher solubility in THF
than alcohols. Theoretically, during antisolvent precipitation
process, smaller particles should precipitate due to an
increasing local supersaturation. However, the result showed
that final particle size of the spray-dried particles from THF
was much larger than those from alcohols because a higher
concentration of isoxyl was present in one atomized droplet
during spray drying.
Table V. The Deposition Profile of Each Isoxyl Powder (n=3)
Unprocessed VRSA=1:1 VRSA=1:2 VRSA=1:5
FPF (%) 6.94±2.34 8.76±2.61 12.57±3.35 9.23±1.65
Dispersibility (%) 8.84±3.32 10.52±4.20 16.63±3.97 12.26±2.90
Percent emission (%) 78.46±2.97 74.90±6.44 75.43±5.74 76.03±5.20
Percent recovery (%) 103.08±2.43 93.43±0.64 94.52±4.53 101.76±2.76






FPF (%) 5.4±1.7 8.4±1.6
Dispersibility (%) 5.8±1.9 8.7±1.7
Percent emission (%) 94.2±2.3 96.6±0.2
Percent recovery (%) 91.1±3.1 97.4±1.8
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The spray-drying method failed to produce isoxyl nano-
particle aggregates due to irreversible agglomeration which
commonly occurs. The isoxyl nanoparticles can only exist as
separate particles in a dilute suspension. In order to conduct
in vivo disposition and efficacy studies, this diluted nano-
particle suspension can be made immediately prior to
delivery by nebulizer. The spray-dried nanoparticle aggre-
gates may be prepared by using appropriate surfactants and/
or bulking agents. Theoretically, appropriate stabilizers can
slow growth of the particles by condensation and coagulation,
which reduces particle sizes. Stabilizers and bulking agents
can also cover the precipitating particles and prevent them
from agglomerating in the drying process and during a long-
term storage. The bulking agent, mannitol, was evaluated in
the study. Nanoparticle aggregates were produced, but these
particles were heterodisperse. Therefore, either mannitol
itself or the amount of mannitol was not sufficient to prevent
nanoparticle agglomeration. Further studies are needed to
screen suitable surfactants or bulking agents for isoxyl nano-
particle preparation. The choice of surfactants is very limited
for pulmonary delivery. Sodium oleate, sodium stearate, cetyl
alcohol, tyloxapol, pluronics, lactose, mannitol, polyvinyl
alcohol, polyethylene glycol, and hydroxylpropylmethylcellu-
lose may be considered, although not all of these are present
in approved products. Some of them are present in Food and
Drug Administration-approved inhalation products, while
some of them have been studied extensively and are generally
recognized as safe. Theoretically, 30–40% w/w of these
stabilizing agents is required to keep nanoparticles with
diameters between 120 and 300 nm separate (39).
The crystalline/amorphous states influence many phys-
icochemical properties of drugs such as saturation solubility,
moisture sorption, and particle stability (40,41). Isoxyl is
known to exist in two different crystal forms. The needle
crystals by crystallization from ethanol have higher melting
point of 149°C (ΔH=98 J/g) and lower aqueous solubility of
0.88 μg/ml than these from hexane that have melting point of
141°C (ΔH=77 J/g) and aqueous solubility of 17.8 μg/ml (42).
During synthesis, isoxyl was purified by crystallization of the
drug from ethanol (43). As expected, DSC profiles showed
that the commercial isoxyl powder contains crystal form I and
a large quantity of residual ethanol. In comparison, micro-
particle processing improved properties of isoxyl in the
following ways: (1) Spray drying completely removed the
residual ethanol; (2) conversion of isoxyl crystal form I to
form II occurred. These phenomena contributed to expect-
ations of much higher solubility. However, it remains to be
established whether polymorph conversion occurred during
precipitation from isopropanol/water or spray drying.
The needle-shaped isoxyl particles generated from the
injection method and lyophilization exhibited higher FPF and
lower emitted dose than those spherical particles from the
nozzle mixing and spray drying. Theoretically, particle shape
greatly impacts on their dispersion and aerodynamic behavior
(44,45). Inspiratory flow fluidizes and deaggregates particles
delivered for the Inhalator®, a passive dry powder inhaler.
Dispersion of particles composes several processes: dilation,
flow, fluidization, and deaggregation. The interparticulate
interaction between elongated particles is very unstable.
After the elongated particles are dispersed, most of them
line up along air streams. As a result, their aerodynamic
diameters only depend on their shortest dimension and
independent of their length. When these particles are inhaled
to the respiratory tract, they will travel further and achieve
better deposition in the deep lung than the spherical particles
with the same geometric diameters (31,44–47). Consequently,
the elongated particles achieved high FPF due to apparently
good dispersion and aerodynamic properties. However, the
flow property of needle-shaped particles is worse than
spherical particle. This caused more particles to adhere to
the wall of capsule inside the device and resulted in lower
emitted dose. The spray-dried isoxyl microparticles were
delivered following blending with carrier lactose, which
increased FPF from 5.4% to 8.4%. Further work is required
to improve the performance of lactose blends with isoxyl.
CONCLUSION
Antisolvent precipitation in water was used to prepare
isoxyl particles suitable for lung delivery. Nanoparticles with a
count median width of 275 nm and a count median length of
495 nm were produced using isopropanol as a solvent and a
VRSA equal to 1:5. Spray drying failed to collect these
nanoparticles but generated near spherical microparticles with
a count median diameter of 1–2 µm. Addition of mannitol in
antisolvent at a drug to mannitol ration of 1:4.4 during
processing produced isoxyl nanoparticle aggregates. A range
of microparticle and nanoparticle preparations has been
evaluated. Further work on their delivery as aerosols is required
to assess the potential for inhaled treatment of tuberculosis.
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